Edition:
United States

Cerecor Inc (CERC.OQ)

CERC.OQ on NASDAQ Stock Exchange Capital Market

1.94USD
15 Dec 2017
Change (% chg)

$0.03 (+1.57%)
Prev Close
$1.91
Open
$1.92
Day's High
$1.99
Day's Low
$1.88
Volume
49,087
Avg. Vol
90,525
52-wk High
$2.63
52-wk Low
$0.34

Latest Key Developments (Source: Significant Developments)

Cerecor announces leadership changes
Friday, 17 Nov 2017 08:30am EST 

Nov 17 (Reuters) - Cerecor Inc :Cerecor announces leadership changes.Cerecor Inc - ‍Interim Chief Executive Officer John Kaiser and Chief Medical Officer Dr. Ronald Marcus stepping down​.Cerecor Inc - ‍Appoints Randal O. Jones and Robert C. Moscato, Jr. to board of directors​.Cerecor Inc - ‍ Names Robert Moscato as president and Chief Operating Officer​.Cerecor Inc - ‍Mariam Morris will continue as Cerecor's chief financial officer​.  Full Article

Cerecor reports Q3 earnings per share of $0.52
Monday, 6 Nov 2017 08:15am EST 

Nov 6 (Reuters) - Cerecor Inc ::Cerecor Inc reports third quarter 2017 financial results.Q3 earnings per share $0.52.As of Sept 30, cash and cash equivalents were $24.0 million, escrowed cash receivable was $3.75 million and current liabilities were $4.8 million​.Expect existing cash and cash equivalents, initial proceeds from Janssen sale will fund operating expenditures through at least 2018​.  Full Article

Cerecor Inc says Uli Hacksell retires as CEO, president
Monday, 14 Aug 2017 08:04am EDT 

Aug 14 (Reuters) - Cerecor Inc :Cerecor Inc announces retirement of Dr. Uli Hacksell as president and chief executive officer.Cerecor Inc says John Kaiser, chief business officer of Cerecor, has been appointed interim chief executive officer.Cerecor Inc says board of directors has initiated a search for a permanent chief executive officer.Cerecor Inc says Hacksell will stay on as chairman of Cerecor's board.  Full Article

Cerecor Inc Q2 loss per share $0.14
Monday, 14 Aug 2017 08:02am EDT 

Aug 14 (Reuters) - Cerecor Inc :Cerecor Inc reports second quarter 2017 financial results.Q2 loss per share $0.14.Q2 revenue $200,000.In August 2017, co sold its world-wide rights of CERC-501 to Janssen in exchange for an initial payment of $25 million​.Under agreement, Janssen will assume ongoing clinical trials and be responsible for any new development or commercialization of CERC-501..Expect existing cash & cash equivalents & proceeds from Janssen sale, to fund operating expenditure requirements through at least 2018.  Full Article

Cerecor files for resale from time to time of up to 29.2 mln shares
Friday, 26 May 2017 07:27am EDT 

May 26 (Reuters) - Cerecor Inc ::Files for resale from time to time of up to 29.2 million shares of its common stock - SEC filing.Says it is not selling any shares of common stock and will not receive any proceeds from the sale.  Full Article

Cerecor Q1 loss per share $0.19
Tuesday, 9 May 2017 08:30am EDT 

May 9 (Reuters) - Cerecor Inc :Cerecor inc. Reports first quarter 2017 financial results.Q1 loss per share $0.19.Q1 revenue $400,000.Cerecor inc - completed a private offering with armistice capital that should support company's operations through 2017.  Full Article

CERECOR ENGAGES SUNTRUST ROBINSON HUMPHREY TO ASSIST WITH REVIEW OF STRATEGIC ALTERNATIVES
Tuesday, 7 Feb 2017 09:32am EST 

Cerecor Inc : CERECOR ENGAGES SUNTRUST ROBINSON HUMPHREY TO ASSIST WITH REVIEW OF STRATEGIC ALTERNATIVES . HAS INITIATED A PROCESS TO EXPLORE AND REVIEW A RANGE OF STRATEGIC ALTERNATIVES .SAYS STRATEGIC ALTERNATIVES THAT MAY BE EXPLORED OR EVALUATED AS PART OF THIS PROCESS INCLUDE AN ACQUISITION, MERGER, BUSINESS COMBINATION.  Full Article

Cerecor announces at-the-market equity offering program
Friday, 27 Jan 2017 04:20pm EST 

Cerecor Inc - : Cerecor announces at-the-market equity offering program . Intends to use net proceeds from at--market offering program, to partially fund research and development of CERC-501 and CERC-611 .Equity distribution agreement with Maxim Group, pursuant to which co to offer and sell shares of its stock of up to $12 million.  Full Article

Cerecor reports top-line data from CERC-301 Phase 2 study
Tuesday, 29 Nov 2016 04:01pm EST 

Cerecor Inc : Cerecor reports top-line data from CERC-301 Phase 2 study for major depressive disorder . Says CERC-301 misses primary endpoint .Cerecor Inc says significant improvement was not observed on other secondary endpoints evaluated to date.  Full Article

Cerecor announces last patient enrolled in phase 2 clinical trial with CERC-501 for smoking cessation
Tuesday, 6 Sep 2016 09:10am EDT 

Cerecor Inc : Cerecor Announces Last Patient Enrolled In Phase 2 Clinical Trial With CERC-501 for smoking cessation . Top-Line phase 2 data expected in December 2016 .Planning to initiate a phase 2 study with CERC-501 as an adjunctive treatment of MDD in 2017.  Full Article

BRIEF-Cerecor announces leadership changes

* Cerecor Inc - ‍Interim Chief Executive Officer John Kaiser and Chief Medical Officer Dr. Ronald Marcus stepping down​